SCHEMBL607614

SCHEMBL607614

CCCCc1ccc(C(N)=O)cc1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RARB P10826 6/20 0.62
PLK1 P53350 1/20 0.62
THRA P10827 7/20 0.61
THRB P10828 7/20 0.61
ALDH1A1 P00352 2/20 0.58
HPGD P15428 1/20 0.58
HSD17B10 Q99714 1/20 0.58
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
RARA P10276 1/20 0.54
MAPT P10636 1/20 0.54
MTOR P42345 1/20 0.54
TRPV1 Q8NER1 1/20 0.54
MPL P40238 1/20 0.52
CA2 P00918 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15750344 0.94 RARB (0.72) RARBPLK1THRATHRBALDH1A1
SCHEMBL2677626 0.94 RARB (0.64) RARBTHRATHRBALDH1A1MEN1
SCHEMBL75644 0.92 THRA (0.65) RARBTHRATHRBALDH1A1MEN1
SCHEMBL6835676 0.92 THRA (0.65) RARBTHRATHRBALDH1A1MEN1
SCHEMBL1327143 0.92 THRA (0.65) RARBTHRATHRBALDH1A1MEN1
Hydrochloric Acid SCHEMBL11612937 0.92 RARB (0.62) RARBTHRATHRBALDH1A1MEN1
SCHEMBL4931942 0.92 THRA (0.65) RARBTHRATHRBALDH1A1MEN1
SCHEMBL351935 0.92 THRA (0.65) RARBTHRATHRBALDH1A1MEN1
SCHEMBL13617729 0.92 THRA (0.65) RARBTHRATHRBALDH1A1MEN1
Hydrochloric Acid SCHEMBL11664844 0.91 THRA (0.63) RARBTHRATHRBALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115044275-B Pipeline protective coating and production process thereof 山东佰盛能源科技有限公司 2023-05-02 CN claimed
CN-115044275-A Pipeline protection coating and production process thereof 山东佰盛能源科技有限公司 2022-09-13 CN claimed
CN-109415325-A Prepare polymorphous method of 3- [5- amino -4- (3- cyanobenzoyl)-pyrazol-1-yl]-N- cyclopropyl -4- methyl benzamide 梅里奥生物制药1有限公司 2019-03-01 CN claimed
US-20170305859-A1 An Anticonvulsant Compound ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) 2017-10-26 US claimed
EP-3191088-A1 AN ANTICONVULSANT COMPOUND Royal Holloway And Bedford New College (GB) 2017-07-19 EP claimed
WO-2016038379-A1 AN ANTICONVULSANT COMPOUND ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) 2016-03-17 WO claimed
EP-2480532-B1 PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS HOFFMANN LA ROCHE (CH) 2013-11-20 EP claimed
US-8546575-B2 NIP thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydroge-nase-1 MERCK PATENT GMBH (DE) 2013-10-01 US claimed
EP-2074089-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2013-09-18 EP claimed
EP-2271405-B1 NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 MERCK PATENT GMBH (DE) 2013-07-24 EP claimed
EP-1660507-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2006-05-31 EP claimed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 US claimed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 WO claimed
EP-1126833-A4 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES INC (US) 2004-09-08 EP claimed
WO-2004043951-A1 PYRAZOLE DERIVATIVES AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS CAREX S.A. (FR) 2004-05-27 WO claimed
US-6617466-B1 Having a heteroatom ligand containing an element with a coordination number of three from Group V A or a coordination number of two from Group VI A attached to the ring through a hydrocarbylene, silane or germanium group EXXONMOBIL CHEMICAL PATENTS INC. 2003-09-09 US claimed
EP-1150565-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION bioscience AG (DE) 2001-11-07 EP claimed
EP-1126833-A2 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2001-08-29 EP claimed
WO-2000045635-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2000-08-10 WO claimed
WO-2000025768-A1 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2000-05-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107307-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 RARB 2234/4885PLK1 1043/4885THRA 4066/4885
US-20170305859-A1 An Anticonvulsant Compound PSEN2, BACE2, APP RARB 2779/4885PLK1 979/4885THRA 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.